FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Allan Rettie

Research Profile

Chemicals & Drugs

Anatomy

Concepts & Ideas

Living Beings

Co-author Network

Publications

TOP 3
Paul E Baker; Megan Cartwright; Aila L Co; Toby B Cole; Jerry H Kim; Yvonne S Lin; Allan E Rettie; Stephanie M Suzuki; Kenneth E Thummel; Clement E Furlong
Identifying safer anti-wear triaryl phosphate additives for jet engine lubricants.
Mariko Nakano; Helmut Hanenberg; Edward J Kelly; Constanze Wiek; Allan E Rettie
CYP4V2 in Bietti's crystalline dystrophy: ocular localization, metabolism of ω-3-polyunsaturated fatty acids, and functional deficit of the p.H331P variant.
Federico Innocenti; Gregory M Cooper; Ian B Stanaway; Eric Gamazon; Joshua D Smith; Snezana Mirkov; Jacqueline Ramirez; Wanqing Liu; Yvonne S Lin; Cliona Moloney; Shelly Force Aldred; Nathan D Trinklein; Erin G Schuetz; Deborah A Nickerson; Ken E Thummel; Mark J Rieder; Allan E Rettie; Mark J Ratain; Nancy J Cox; Christopher D Brown
Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Allan Rettie (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Paul E Baker; Megan Cartwright; Aila L Co; Toby B Cole; Jerry H Kim; Yvonne S Lin; Allan E Rettie; Stephanie M Suzuki; Kenneth E Thummel; Clement E Furlong
Identifying safer anti-wear triaryl phosphate additives for jet engine lubricants.
Chemico-biological interactions 2013;203(1):257-64.
2012: Mariko Nakano; Helmut Hanenberg; Edward J Kelly; Constanze Wiek; Allan E Rettie
CYP4V2 in Bietti's crystalline dystrophy: ocular localization, metabolism of ω-3-polyunsaturated fatty acids, and functional deficit of the p.H331P variant.
Molecular pharmacology 2012;82(4):679-86.
2011: Federico Innocenti; Gregory M Cooper; Ian B Stanaway; Eric Gamazon; Joshua D Smith; Snezana Mirkov; Jacqueline Ramirez; Wanqing Liu; Yvonne S Lin; Cliona Moloney; Shelly Force Aldred; Nathan D Trinklein; Erin G Schuetz; Deborah A Nickerson; Ken E Thummel; Mark J Rieder; Allan E Rettie; Mark J Ratain; Nancy J Cox; Christopher D Brown
Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue.
PLoS genetics 2011;7(5):e1002078.
2011: Edward J Kelly; Mariko Nakano; Priyanka Rohatgi; Vladimir Yarov-Yarovoy; Allan E Rettie
Finding homes for orphan cytochrome P450s: CYP4V2 and CYP4F22 in disease states.
Molecular interventions 2011;11(2):124-32.
2011: Thomas A Baillie; Allan E Rettie
Role of biotransformation in drug-induced toxicity: influence of intra- and inter-species differences in drug metabolism.
Drug metabolism and pharmacokinetics 2011;26(1):15-29.
2010: Arthur G Roberts; Matthew J Cheesman; Andrew Primak; Michael K Bowman; William M Atkins; Allan E Rettie
Intramolecular heme ligation of the cytochrome P450 2C9 R108H mutant demonstrates pronounced conformational flexibility of the B-C loop region: implications for substrate binding.
Biochemistry 2010;49(40):8700-8.
2009: Mariko Nakano; Edward J Kelly; Allan E Rettie
Expression and characterization of CYP4V2 as a fatty acid omega-hydroxylase.
Drug metabolism and disposition: the biological fate of chemicals 2009;37(11):2119-22.
2009: Matthew G McDonald; Mark J Rieder; Mariko Nakano; Clara K Hsia; Allan E Rettie
CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant.
Molecular pharmacology 2009;75(6):1337-46.
2009: Carrie M Mosher; Guoying Tai; Allan E Rettie
CYP2C9 amino acid residues influencing phenytoin turnover and metabolite regio- and stereochemistry.
The Journal of pharmacology and experimental therapeutics 2009;329(3):938-44.
2008: Carrie M Mosher; Matthew A Hummel; Timothy S Tracy; Allan E Rettie
Functional analysis of phenylalanine residues in the active site of cytochrome P450 2C9.
Biochemistry 2008;47(45):11725-34.
2008: Guoying Tai; Leslie J Dickmann; Nicholas Matovic; James J DeVoss; Elizabeth M J Gillam; Allan E Rettie
Re-engineering of CYP2C9 to probe acid-base substrate selectivity.
Drug metabolism and disposition: the biological fate of chemicals 2008;36(10):1992-7.
2008: Gregory Cooper; Julie A Johnson; Taimour Y Langaee; Hua Feng; Ian B Stanaway; Ute I Schwarz; Marylyn Ritchie; C Michael Stein; Dan Mark Roden; joshua smith; David L Veenstra; Allan E Rettie; Mark J Rieder
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.
Blood 2008;112(4):1022-7.
2008: Lisa M Meckley; Ann K Wittkowsky; Mark J Rieder; Allan E Rettie; David L Veenstra
An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.
Thrombosis and haemostasis 2008;100(2):229-39.
2008: Melissa Kramer; Allan E Rettie; Mark J Rieder; Erwin T Cabacungan; Ronald Hines
Novel CYP2C9 promoter variants and assessment of their impact on gene expression.
Molecular pharmacology 2008;73(6):1751-60.
2008: Nicholas Au; Allan E Rettie
Pharmacogenomics of 4-hydroxycoumarin anticoagulants.
Drug metabolism reviews 2008;40(2):355-75.
2008: Allan E Rettie
Bioinformatics and disposition of xenobiotics. Preface.
Drug metabolism reviews 2008;40(2):185.
2007: Matthew G McDonald; Allan E Rettie
Sequential metabolism and bioactivation of the hepatotoxin benzbromarone: formation of glutathione adducts from a catechol intermediate.
Chemical research in toxicology 2007;20(12):1833-42.
2007: Mark J Rieder; Alexander P Reiner; Allan E Rettie
Gamma-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose.
Journal of thrombosis and haemostasis : JTH 2007;5(11):2227-34.
2007: Brian R Baer; Kent L Kunze; Allan E Rettie
Mechanism of formation of the ester linkage between heme and Glu310 of CYP4B1: 18O protein labeling studies.
Biochemistry 2007;46(41):11598-605.
2007: Catherine K Yeung; Elinor T Adman; Allan E Rettie
Functional characterization of genetic variants of human FMO3 associated with trimethylaminuria.
Archives of biochemistry and biophysics 2007;464(2):251-9.
2006: Allan E Rettie; Federico M Farin; Nitasha G Beri; Sengkeo L Srinouanprachanh; Mark J Rieder; Henk H Thijssen
A case study of acenocoumarol sensitivity and genotype-phenotype discordancy explained by combinations of polymorphisms in VKORC1 and CYP2C9.
British journal of clinical pharmacology 2006;62(5):617-20.
2006: Allan E Rettie; Guoying Tai
The pharmocogenomics of warfarin: closing in on personalized medicine.
Molecular interventions 2006;6(4):223-7.
2006: Mary F Paine; Heather L Hart; Shana S Ludington; Robert L Haining; Allan E Rettie; Darryl C Zeldin
The human intestinal cytochrome P450 "pie".
Drug metabolism and disposition: the biological fate of chemicals 2006;34(5):880-6.
2006: Brian R Baer; Allan E Rettie
CYP4B1: an enigmatic P450 at the interface between xenobiotic and endobiotic metabolism.
Drug metabolism reviews 2006;38(3):451-76.
2006: Mary Beth Genter; Garold S Yost; Allan E Rettie
Localization of CYP4B1 in the rat nasal cavity and analysis of CYPs as secreted proteins.
Journal of biochemical and molecular toxicology 2006;20(3):139-41.
2006: Catherine K Yeung; Allan E Rettie
Prochiral sulfoxidation as a probe for flavin-containing monooxygenases.
Methods in molecular biology (Clifton, N.J.) 2006;320():163-72.
2006: Catherine K Yeung; Allan E Rettie
Benzydamine N-oxygenation as a measure of flavin-containing monooxygenase activity.
Methods in molecular biology (Clifton, N.J.) 2006;320():157-62.
2005: Brian R Baer; Jason T Schuman; A Patricia Campbell; Matthew J Cheesman; Mariko Nakano; Nicole Moguilevsky; Kent L Kunze; Allan E Rettie
Sites of covalent attachment of CYP4 enzymes to heme: evidence for microheterogeneity of P450 heme orientation.
Biochemistry 2005;44(42):13914-20.
2005: Albert W Dreisbach; Shanker Japa; Aster Sigel; Melissa B Parenti; Arthur E Hess; Sengkeo L Srinouanprachanh; Allan E Rettie; Helen Kim; Federico M Farin; L Lee Hamm; Juan J L Lertora
The Prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension.
American journal of hypertension 2005;18(10):1276-81.
2005: David L Veenstra; Joyce H S You; Mark J Rieder; Federico M Farin; Hui-Wen Wilkerson; David K Blough; Gregory Cheng; Allan E Rettie
Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population.
Pharmacogenetics and genomics 2005;15(10):687-91.
2005: Matthew A Hummel; Charles W Locuson; Peter Gannett; Dan A Rock; Carrie M Mosher; Allan E Rettie; Timothy S Tracy
CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variant.
Molecular pharmacology 2005;68(3):644-51.
2005: Guoying Tai; Federico M Farin; Mark J Rieder; Albert W Dreisbach; David L Veenstra; Christophe Verlinde; Allan E Rettie
In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose.
Pharmacogenetics and genomics 2005;15(7):475-81.
2005: Mark J Rieder; Alexander P Reiner; Brian F Gage; Deborah A Nickerson; Charles Eby; howard mcleod; David K Blough; Kenneth E Thummel; David L Veenstra; Allan E Rettie
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.
The New England journal of medicine 2005;352(22):2285-93.
2005: David L Veenstra; David K Blough; Mitchell K Higashi; Federico M Farin; Sengkeo Srinouanprachan; Mark J Rieder; Allan E Rettie
CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes.
Clinical pharmacology and therapeutics 2005;77(5):353-64.
2005: Rheem A Totah; Allan E Rettie
Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance.
Clinical pharmacology and therapeutics 2005;77(5):341-52.
2005: Brian R Baer; Allan E Rettie; Kirk R Henne
Bioactivation of 4-ipomeanol by CYP4B1: adduct characterization and evidence for an enedial intermediate.
Chemical research in toxicology 2005;18(5):855-64.
2005: Allan E Rettie; Jeffrey P Jones
Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics.
Annual review of pharmacology and toxicology 2005;45():477-94.
2004: Charles W Locuson; Hisashi Suzuki; Allan E Rettie; Jeffrey P Jones
Charge and substituent effects on affinity and metabolism of benzbromarone-based CYP2C19 inhibitors.
Journal of medicinal chemistry 2004;47(27):6768-76.
2004: Vinayak P Hosagrahara; Allan E Rettie; Christopher Hassett; Curtis J Omiecinski
Functional analysis of human microsomal epoxide hydrolase genetic variants.
Chemico-biological interactions 2004;150(2):149-59.
2004: Hisashi Suzuki; M Byron Kneller; Dan A Rock; Jeffrey P Jones; William F Trager; Allan E Rettie
Active-site characteristics of CYP2C19 and CYP2C9 probed with hydantoin and barbiturate inhibitors.
Archives of biochemistry and biophysics 2004;429(1):1-15.
2004: Matthew A Hummel; Leslie J Dickmann; Allan E Rettie; Robert L Haining; Timothy S Tracy
Differential activation of CYP2C9 variants by dapsone.
Biochemical pharmacology 2004;67(10):1831-41.
2004: Leslie J Dickmann; Charles W Locuson; Jeffrey P Jones; Allan E Rettie
Differential roles of Arg97, Asp293, and Arg108 in enzyme stability and substrate specificity of CYP2C9.
Molecular pharmacology 2004;65(4):842-50.
2004: Sevasti B Koukouritaki; Jason R Manro; Sandra A Marsh; Jeffrey C Stevens; Allan E Rettie; D Gail McCarver; Ronald Hines
Developmental expression of human hepatic CYP2C9 and CYP2C19.
The Journal of pharmacology and experimental therapeutics 2004;308(3):965-74.
2003: Matthew J Cheesman; M Byron Kneller; Allan E Rettie
Critical role of histidine residues in cyclohexanone monooxygenase expression, cofactor binding and catalysis.
Chemico-biological interactions 2003;146(2):157-64.
2003: Matthew J Cheesman; Brian R Baer; Yi-Min Zheng; Elizabeth M J Gillam; Allan E Rettie
Rabbit CYP4B1 engineered for high-level expression in Escherichia coli: ligand stabilization and processing of the N-terminus and heme prosthetic group.
Archives of biochemistry and biophysics 2003;416(1):17-24.
2003: Albert W Dreisbach; Shanker Japa; Aster B Gebrekal; Sarah E Mowry; Juan J L Lertora; Burde L Kamath; Allan E Rettie
Cytochrome P4502C9 activity in end-stage renal disease.
Clinical pharmacology and therapeutics 2003;73(5):475-7.
2003: Yi-Min Zheng; Brian R Baer; M Byron Kneller; Kirk R Henne; Kent L Kunze; Allan E Rettie
Covalent heme binding to CYP4B1 via Glu310 and a carbocation porphyrin intermediate.
Biochemistry 2003;42(15):4601-6.
2003: Allan E Rettie; Guoying Tai; David L Veenstra; Federico M Farin; Sengkeo Srinouanprachan; Yvonne S Lin; Kenneth E Thummel; Ronald Hines
CYP2C9 exon 4 mutations and warfarin dose phenotype in Asians.
Blood 2003;101(7):2896-7.
2003: Yi-Min Zheng; Kirk R Henne; Patrick Charmley; Richard B Kim; D Gail McCarver; Erwin T Cabacungan; Ronald Hines; Allan E Rettie
Genotyping and site-directed mutagenesis of a cytochrome P450 meander Pro-X-Arg motif critical to CYP4B1 catalysis.
Toxicology and applied pharmacology 2003;186(2):119-26.
2002: Aiming Yu; Byron M Kneller; Allan E Rettie; Robert L Haining
Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms.
The Journal of pharmacology and experimental therapeutics 2002;303(3):1291-300.
2002: Mitchell K Higashi; David L Veenstra; L Midori Kondo; Ann K Wittkowsky; Sengkeo L Srinouanprachanh; Federico M Farin; Allan E Rettie
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.
JAMA : the journal of the American Medical Association 2002;287(13):1690-8.
2002: Timothy S Tracy; J Matthew Hutzler; Robert L Haining; Allan E Rettie; Matthew A Hummel; Leslie J Dickmann
Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(4):385-90.
2002: Hisashi Suzuki; M Byron Kneller; Robert L Haining; William F Trager; Allan E Rettie
(+)-N-3-Benzyl-nirvanol and (-)-N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(3):235-9.
2002: Sevasti B Koukouritaki; Pippa Simpson; Catherine K Yeung; Allan E Rettie; Ronald Hines
Human hepatic flavin-containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression.
Pediatric research 2002;51(2):236-43.
2001: Kirk R Henne; Kent L Kunze; Yi-Min Zheng; Peter Christmas; Roy J Soberman; Allan E Rettie
Covalent linkage of prosthetic heme to CYP4 family P450 enzymes.
Biochemistry 2001;40(43):12925-31.
2001: Carlos A Gartner; SJ Thompson; Allan E Rettie; Sidney D Nelson
Human aromatase in high yield and purity by perfusion chromatography and its characterization by difference spectroscopy and mass spectrometry.
Protein expression and purification 2001;22(3):443-54.
2001: Leslie J Dickmann; Allan E Rettie; M Byron Kneller; Richard B Kim; A J Wood; C M Stein; G R Wilkinson; Ute I Schwarz
Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans.
Molecular pharmacology 2001;60(2):382-7.
2001: Kirk R Henne; Michael B Fisher; K R Iyer; DH Lang; William F Trager; Allan E Rettie
Active site characteristics of CYP4B1 probed with aromatic ligands.
Biochemistry 2001;40(29):8597-605.
2001: Jooran S Kim; Anne N Nafziger; Andrea Gaedigk; Leslie J Dickmann; Allan E Rettie; Joseph S Bertino
Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe.
Journal of clinical pharmacology 2001;41(7):715-22.
2001: M He; Allan E Rettie; J Neal; William F Trager
Metabolism of sulfinpyrazone sulfide and sulfinpyrazone by human liver microsomes and cDNA-expressed cytochrome P450s.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(5):701-11.
2001: M Byron Kneller; Matthew J Cheesman; Allan E Rettie
ESI- and MALDI-MS analysis of cyclohexanone monooxygenase from acinetobacter NCIB 9871.
Biochemical and biophysical research communications 2001;282(4):899-903.
2001: Tansel Kilicarslan; Robert L Haining; Allan E Rettie; Usoa E Busto; Rachel F Tyndale; Edward M Sellers
Flunitrazepam metabolism by cytochrome P450S 2C19 and 3A4.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(4 Pt 1):460-5.
2001: Matthew J Cheesman; M Byron Kneller; Edward J Kelly; SJ Thompson; Catherine K Yeung; David Eaton; Allan E Rettie
Purification and characterization of hexahistidine-tagged cyclohexanone monooxygenase expressed in Saccharomyces cerevisiae and Escherichia coli.
Protein expression and purification 2001;21(1):81-6.
2000: H Dong; Robert L Haining; Kenneth E Thummel; Allan E Rettie; Sidney D Nelson
Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen.
Drug metabolism and disposition: the biological fate of chemicals 2000;28(12):1397-400.
2000: DH Lang; Allan E Rettie
In vitro evaluation of potential in vivo probes for human flavin-containing monooxygenase (FMO): metabolism of benzydamine and caffeine by FMO and P450 isoforms.
British journal of clinical pharmacology 2000;50(4):311-4.
2000: Catherine K Yeung; DH Lang; Kenneth E Thummel; Allan E Rettie
Immunoquantitation of FMO1 in human liver, kidney, and intestine.
Drug metabolism and disposition: the biological fate of chemicals 2000;28(9):1107-11.
2000: S Rao; R Aoyama; M Schrag; William F Trager; Allan E Rettie; Jeffrey P Jones
A refined 3-dimensional QSAR of cytochrome P450 2C9: computational predictions of drug interactions.
Journal of medicinal chemistry 2000;43(15):2789-96.
2000: Allan E Rettie; DH Lang
Can caffeine metabolism be used as an in-vivo probe for human flavin-containing monooxygenase activity?
Pharmacogenetics 2000;10(3):275-7.
1999: M He; Kenneth R Korzekwa; Jeffrey P Jones; Allan E Rettie; William F Trager
Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9.
Archives of biochemistry and biophysics 1999;372(1):16-28.
1999: Allan E Rettie; Robert L Haining; M Bajpai; René H Levy
A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin.
Epilepsy research 1999;35(3):253-5.
1999: Robert L Haining; Jeffrey P Jones; Kirk R Henne; Michael B Fisher; Dennis R Koop; William F Trager; Allan E Rettie
Enzymatic determinants of the substrate specificity of CYP2C9: role of B'-C loop residues in providing the pi-stacking anchor site for warfarin binding.
Biochemistry 1999;38(11):3285-92.
1999: Luke Lightning; Raimund Peter; AP Hunter; Robert L Haining; Allan E Rettie; Thomas Friedberg; Michael P Pritchard; Magang Shou; Thomas H Rushmore; William F Trager
Electrospray ionization mass spectrometric analysis of intact cytochrome P450: identification of tienilic acid adducts to P450 2C9.
Biochemistry 1999;38(8):2312-9.
1998: DH Lang; Catherine K Yeung; Raimund Peter; Catherine A Ibarra; R Gasser; K Itagaki; RM Philpot; Allan E Rettie
Isoform specificity of trimethylamine N-oxygenation by human flavin-containing monooxygenase (FMO) and P450 enzymes: selective catalysis by FMO3.
Biochemical pharmacology 1998;56(8):1005-12.
1998: Yi-Min Zheng; Michael B Fisher; N Yokotani; Yoshiaki Fujii-Kuriyama; Allan E Rettie
Identification of a meander region proline residue critical for heme binding to cytochrome P450: implications for the catalytic function of human CYP4B1.
Biochemistry 1998;37(37):12847-51.
1998: Michael B Fisher; SJ Thompson; Vera Ribeiro; M C Lechner; Allan E Rettie
P450-catalyzed in-chain desaturation of valproic acid: isoform selectivity and mechanism of formation of Delta 3-valproic acid generated by baculovirus-expressed CYP3A1.
Archives of biochemistry and biophysics 1998;356(1):63-70.
1998: Michael B Fisher; Yi-Min Zheng; Allan E Rettie
Positional specificity of rabbit CYP4B1 for omega-hydroxylation1 of short-medium chain fatty acids and hydrocarbons.
Biochemical and biophysical research communications 1998;248(2):352-5.
1998: Kirk R Henne; A Gaedigk; G Gupta; J S Leeder; Allan E Rettie
Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype.
Journal of chromatography. B, Biomedical sciences and applications 1998;710(1-2):143-8.
1998: J K Racha; Allan E Rettie; Kent L Kunze
Mechanism-based inactivation of human cytochrome P450 1A2 by furafylline: detection of a 1:1 adduct to protein and evidence for the formation of a novel imidazomethide intermediate.
Biochemistry 1998;37(20):7407-19.
1998: W Chen; Luke Lightning; SJ Thompson; Raimund Peter; Allan E Rettie; William F Trager; Sidney D Nelson
Oxidation of acetaminophen to its toxic quinone imine and nontoxic catechol metabolites by baculovirus-expressed and purified human cytochromes P450 2E1 and 2A6.
Chemical research in toxicology 1998;11(4):295-301.
1998: Kenneth R Korzekwa; N Krishnamachary; Magang Shou; A Ogai; Robert A Parise; Allan E Rettie; F J Gonzalez; Timothy S Tracy
Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites.
Biochemistry 1998;37(12):4137-47.
1998: X Guan; Michael B Fisher; DH Lang; Yi-Min Zheng; Dennis R Koop; Allan E Rettie
Cytochrome P450-dependent desaturation of lauric acid: isoform selectivity and mechanism of formation of 11-dodecenoic acid.
Chemico-biological interactions 1998;110(1-2):103-21.
1997: Luke Lightning; Raimund Peter; SJ Thompson; Allan E Rettie; William F Trager
Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen.
Drug metabolism and disposition: the biological fate of chemicals 1997;25(12):1407-15.
1997: A J Sadeque; Michael B Fisher; Kenneth R Korzekwa; F J Gonzalez; Allan E Rettie
Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid.
The Journal of pharmacology and experimental therapeutics 1997;283(2):698-703.
1997: D J Steward; Robert L Haining; Kirk R Henne; G Davis; Thomas H Rushmore; William F Trager; Allan E Rettie
Genetic association between sensitivity to warfarin and expression of CYP2C9*3.
Pharmacogenetics 1997;7(5):361-7.
1997: DH Lang; Allan E Rettie; R H Böcker
Identification of enzymes involved in the metabolism of atrazine, terbuthylazine, ametryne, and terbutryne in human liver microsomes.
Chemical research in toxicology 1997;10(9):1037-44.
1997: Robert L Haining; AP Hunter; A J Sadeque; RM Philpot; Allan E Rettie
Baculovirus-mediated expression and purification of human FMO3: catalytic, immunochemical, and structural characterization.
Drug metabolism and disposition: the biological fate of chemicals 1997;25(7):790-7.
1997: M Tugnait; Edward M Hawes; Gordon McKay; Allan E Rettie; Robert L Haining; Kamal K Midha
N-oxygenation of clozapine by flavin-containing monooxygenase.
Drug metabolism and disposition: the biological fate of chemicals 1997;25(4):524-7.
1996: Robert L Haining; A P Hunter; M E Veronese; William F Trager; Allan E Rettie
Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms.
Archives of biochemistry and biophysics 1996;333(2):447-58.
1996: L C Wienkers; colleen johnson wurden; E Storch; Kent L Kunze; Allan E Rettie; William F Trager
Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19.
Drug metabolism and disposition: the biological fate of chemicals 1996;24(5):610-4.
1995: Michael B Fisher; M P Lawton; Emmanuel Atta-Asafo-Adjei; RM Philpot; Allan E Rettie
Selectivity of flavin-containing monooxygenase 5 for the (S)-sulfoxidation of short-chain aralkyl sulfides.
Drug metabolism and disposition: the biological fate of chemicals 1995;23(12):1431-3.
1995: D H Slone; E P Gallagher; H S Ramsdell; Allan E Rettie; P L Stapleton; L G Berlad; David Eaton
Human variability in hepatic glutathione S-transferase-mediated conjugation of aflatoxin B1-epoxide and other substrates.
Pharmacogenetics 1995;5(4):224-33.
1995: Allan E Rettie; P R Sheffels; Kenneth R Korzekwa; F J Gonzalez; RM Philpot; Thomas A Baillie
CYP4 isozyme specificity and the relationship between omega-hydroxylation and terminal desaturation of valproic acid.
Biochemistry 1995;34(24):7889-95.
1995: Allan E Rettie; G P Meier; A J Sadeque
Prochiral sulfides as in vitro probes for multiple forms of the flavin-containing monooxygenase.
Chemico-biological interactions 1995;96(1):3-15.
1994: H Y Yang; Q P Lee; Allan E Rettie; Mont R Juchau
Functional cytochrome P4503A isoforms in human embryonic tissues: expression during organogenesis.
Molecular pharmacology 1994;46(5):922-8.
1994: Stephen D Hall; Mitchell A Hamman; Allan E Rettie; L C Wienkers; William F Trager; Mark R VandenBranden; Steven A Wrighton
Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes.
Drug metabolism and disposition: the biological fate of chemicals 1994;22(6):975-8.
1994: Allan E Rettie; M P Lawton; A J Sadeque; G P Meier; RM Philpot
Prochiral sulfoxidation as a probe for multiple forms of the microsomal flavin-containing monooxygenase: studies with rabbit FMO1, FMO2, FMO3, and FMO5 expressed in Escherichia coli.
Archives of biochemistry and biophysics 1994;311(2):369-77.
1994: Allan E Rettie; L C Wienkers; F J Gonzalez; William F Trager; Kenneth R Korzekwa
Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9.
Pharmacogenetics 1994;4(1):39-42.
1993: A J Sadeque; K E Thummel; Allan E Rettie
Purification of macaque liver flavin-containing monooxygenase: a form of the enzyme related immunochemically to an isozyme expressed selectively in adult human liver.
Biochimica et biophysica acta 1993;1162(1-2):127-34.
1993: Steven A Wrighton; Mark R VandenBranden; J C Stevens; L A Shipley; Barbara J Ring; Allan E Rettie; J R Cashman
In vitro methods for assessing human hepatic drug metabolism: their use in drug development.
Drug metabolism reviews 1993;25(4):453-84.
1992: A J Sadeque; A C Eddy; G P Meier; Allan E Rettie
Stereoselective sulfoxidation by human flavin-containing monooxygenase. Evidence for catalytic diversity between hepatic, renal, and fetal forms.
Drug metabolism and disposition: the biological fate of chemicals 1992;20(6):832-9.
1992: Allan E Rettie; Kenneth R Korzekwa; Kent L Kunze; R F Lawrence; A C Eddy; T Aoyama; H V Gelboin; F J Gonzalez; William F Trager
Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions.
Chemical research in toxicology 1992;5(1):54-9.
1990: Allan E Rettie; B D Bogucki; I Lim; G P Meier
Stereoselective sulfoxidation of a series of alkyl p-tolyl sulfides by microsomal and purified flavin-containing monooxygenases.
Molecular pharmacology 1990;37(5):643-51.
1990: Jeffrey P Jones; Allan E Rettie; William F Trager
Intrinsic isotope effects suggest that the reaction coordinate symmetry for the cytochrome P-450 catalyzed hydroxylation of octane is isozyme independent.
Journal of medicinal chemistry 1990;33(4):1242-6.
1990: R F Lawrence; Allan E Rettie; A C Eddy; William F Trager
Chemical synthesis, absolute configuration, and stereochemistry of formation of 10-hydroxywarfarin: a major oxidative metabolite of (+)-(R)-warfarin from hepatic microsomal preparations.
Chirality 1990;2(2):96-105.
1989: B M Kerr; Allan E Rettie; A C Eddy; P Loiseau; M Guyot; Alan J Wilensky; René H Levy
Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: in vitro/in vivo correlation.
Clinical pharmacology and therapeutics 1989;46(1):82-93.
1989: Allan E Rettie; A C Eddy; L D Heimark; M Gibaldi; William F Trager
Characteristics of warfarin hydroxylation catalyzed by human liver microsomes.
Drug metabolism and disposition: the biological fate of chemicals 1989;17(3):265-70.
1988: Allan E Rettie; M Boberg; A W Rettenmeier; Thomas A Baillie
Cytochrome P-450-catalyzed desaturation of valproic acid in vitro. Species differences, induction effects, and mechanistic studies.
The Journal of biological chemistry 1988;263(27):13733-8.
1987: Allan E Rettie; A W Rettenmeier; William N Howald; Thomas A Baillie
Cytochrome P-450--catalyzed formation of delta 4-VPA, a toxic metabolite of valproic acid.
Science (New York, N.Y.) 1987;235(4791):890-3.
1986: Allan E Rettie; A W Rettenmeier; B K Beyer; Thomas A Baillie; M R Juchau
Valproate hydroxylation by human fetal tissues and embryotoxicity of metabolites.
Clinical pharmacology and therapeutics 1986;40(2):172-7.